Immune Checkpoint in Cancer

Description:

Immune checkpoints are co-stimulatory or inhibitory molecules that serve as regulators of T cells function in the tumor microenvironment. Inhibitory immune checkpoints maintain immune homeostasis, down-regulate anti-tumor responses and prevent autoimmunity (Ref.1). Checkpoint pathways involve costimulatory and inhibitory receptors and their ligands. Costimulatory receptors include CD28 and ICOS (inducible T cel[...]

References:

Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.
Tsai HF, Hsu PN.
J Biomed Sci. 2017 May 25;24(1):35. doi: 10.1186/s12929-017-0341-0. Review.
B7 family checkpoint regulators in immune regulation and disease.
Ceeraz S, Nowak EC, Noelle RJ.
Trends Immunol. 2013 Nov;34(11):556-63. doi: 10.1016/j.it.2013.07.003. Review.
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F.
Eur Urol. 2015 Aug;68(2):267-79. doi: 10.1016/j.eururo.2015.02.032. Epub 2015 Mar 29. Review.
Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations.
Davis RJ, Ferris RL, Schmitt NC.
Cancers Head Neck. 2016 Oct 1;1:12. doi: 10.1186/s41199-016-0013-x. eCollection 2016. Review.
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
Nirschl CJ, Drake CG.
Clin Cancer Res. 2013 Sep 15;19(18):4917-24. doi: 10.1158/1078-0432.CCR-12-1972. Review.
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, Saldmann A, Gey A, Oudard S, Tartour E.
ESMO Open. 2017 Jul 3;2(2):e000213. doi: 10.1136/esmoopen-2017-000213. eCollection 2017. Review.
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.
Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J.
J Exp Clin Cancer Res. 2019 Feb 18;38(1):87. doi: 10.1186/s13046-019-1085-3. Review.
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
Wei SC, Duffy CR, Allison JP.
Cancer Discov. 2018 Sep;8(9):1069-1086. doi: 10.1158/2159-8290.CD-18-0367. Epub 2018 Aug 16. Review.
Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
Pico de Coaña Y, Choudhury A, Kiessling R.
Trends Mol Med. 2015 Aug;21(8):482-91. doi: 10.1016/j.molmed.2015.05.005. Epub 2015 Jun 16. Review.

You can get all the details on this pathway through subscription

Pathways

Immune Checkpoint in Cancer

Description:

References:

Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.

B7 family checkpoint regulators in immune regulation and disease.

A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.

Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations.

Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.

Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.

Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.

Databases

Tools

Institutional License

Pathways

Immune Checkpoint in Cancer

Description:

References:

Databases

Tools

Institutional License

Log In